AN EXCELLENT REVIEW OF THE BIOTECH-PHARMA RELATIONSHIP TODAY, where it is clearly more efficient for Big Pharma to make early deals on SME biopharma products, and to focus on the expensive late stages of gaining approval and ultimately, marketing. This whole dynamic, however, has been confounded by the pull-back of VCs from funding early biotech, and the simultaneous effects of the Crisis. No clear answer in sight, except perhaps the serious pain Big Pharma is experiencing as it tries to reinvent itself, opening new possibilities.
http://lnkd.in/62mN2K
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022